文献速递肿瘤 PET/CT神经核医学

动脉内递送89Zr-贝伐珠单抗联合渗透性开放血脑屏障在胶质母细胞瘤小鼠PET成像中的显著优势

A Distinct Advantage to Intraarterial Delivery of 89Zr-Bevacizumab in PET Imaging of Mice With and Without Osmotic Opening of the Blood-Brain Barrier.
PubMed 文献 · J Nucl Med · 2018-10-12

该研究在胶质母细胞瘤(GBM)小鼠模型中,用89Zr标记贝伐珠单抗(89Zr-BVDFO),比较颈动脉与尾静脉输注、血脑屏障完整或甘露醇开放条件下的脑摄取。动态PET及离体生物分布显示,动脉内输注联合甘露醇开放血脑屏障时同侧半球摄取最高(23.58 ± 4.46 %ID/cm3),而静脉输注后开放血脑屏障未导致脑内摄取。

要点

  • 动脉内输注89Zr-BVDFO在输注结束时同侧半球摄取为9.16 ± 2.13 %ID/cm3,对侧信号可忽略。
  • 甘露醇开放血脑屏障后动脉内输注同侧半球摄取更快更高,达23.58 ± 4.46 %ID/cm3,对侧仍可忽略。
  • 静脉输注89Zr-BVDFO后开放血脑屏障未导致脑内放射性示踪剂摄取。

核心结论

  • 研究结果表明,经渗透性开放的血脑屏障动脉内递送贝伐珠单抗入脑是有效的,与静脉途径相反。

研究设计与样本

  • 研究使用89Zr标记的贝伐珠单抗(89Zr-BVDFO,比放射性81.4 ± 7.4 MBq/mg)在胶质母细胞瘤小鼠模型中比较颈动脉与尾静脉输注、血脑屏障完整或甘露醇开放条件下的脑摄取。
  • 采用动态PET监测脑摄取,并在输注后1和24小时进行全身PET/CT,同时进行离体生物分布测定。

主要发现

  • 动脉内给予89Zr-BVDFO导致同侧半球放射性逐渐累积,输注结束时为9.16 ± 2.13 %ID/cm3,对侧半球信号可忽略。
  • 动脉内输注前用甘露醇开放血脑屏障导致同侧半球摄取更快更高(23.58 ± 4.46 %ID/cm3),对侧半球摄取可忽略。
  • 静脉输注89Zr-BVDFO后开放血脑屏障未导致放射性示踪剂在脑内摄取。
  • 离体生物分布结果验证了PET/CT研究结果。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glioblastoma multiforme (GBM) is the most aggressive and common type of brain cancer. Five-year survival rates are below 12%, even with the most aggressive trimodal therapies. Poor blood-brain barrier (BBB) permeability of therapeutics is a major obstacle to efficacy. Intravenous administration of bevacizumab is the standard treatment for GBM. It has been recently demonstrated that a single intraarterial infusion of bevacizumab provides superior therapeutic outcomes in patients with recurrent GBM. Further GBM treatment benefits can be achieved through opening of the BBB before intraarterial infusion of bevacizumab. However, a rationale for intraarterial delivery and BBB opening when delivering antibodies is lacking. A method facilitating quantification of intraarterial delivery of bevacizumab is needed for more effective and personalized GBM treatment. Here, we demonstrate such a method using PET imaging of radiolabeled bevacizumab. Methods: Bevacizumab was conjugated with deferoxamine and subsequently radiolabeled with 89Zr. 89Zr-bevacizumab deferoxamine (89Zr-BVDFO) was prepared with a specific radioactivity of 81.4 ± 7.4 MBq/mg (2.2 ± 0.2 μCi/mg). Brain uptake of 89Zr-BVDFO on carotid artery and tail vein infusion with an intact BBB or with BBB opening with mannitol was initially monitored by dynamic PET, followed by whole-body PET/CT at 1 and 24 h after infusion. Th ex vivo biodistribution of 89Zr-BVDFO was also determined. Results: Intraarterial administration of 89Zr-BVDFO resulted in gradual accumulation of radioactivity in the ipsilateral hemisphere, with 9.16 ± 2.13 percentage injected dose/cm3 at the end of infusion. There was negligible signal observed in the contralateral hemisphere. BBB opening with mannitol before intraarterial infusion of 89Zr-BVDFO resulted in faster and higher uptake in the ipsilateral hemisphere (23.58 ± 4.46 percentage injected dose/cm3) and negligible uptake in the contralateral hemisphere. In contrast, intravenous infusion of 89Zr-BVDFO and subsequent BBB opening did not lead to uptake of radiotracer in the brain. The ex vivo biodistribution results validated the PET/CT studies. Conclusion: Our findings demonstrate that intraarterial delivery of bevacizumab into the brain across an osmotically opened BBB is effective, in contrast to the intravenous route.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lesniak WG, Chu C, Jablonska A, et al. A Distinct Advantage to Intraarterial Delivery of 89Zr-Bevacizumab in PET Imaging of Mice With and Without Osmotic Opening of the Blood-Brain Barrier. J Nucl Med. 2018. PMID: 30315146. doi:10.2967/jnumed.118.218792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。